Breaking News, Collaborations & Alliances

Debiopharm, Alkyon Therapeutics to Research Radioligand Therapies

The research program will combine Debiopharm’s AbYlink conjugation technology with Alkyon’s modular antibody platform and novel targeting approaches to advance targeted radiopharmaceutical treatments.

By: Rachel Klemovitch

Assistant Editor

Debiopharm, a privately owned Swiss biopharmaceutical company, and Alkyon Therapeutics, a biotechnology company pioneering precision-targeted therapies, signed a co-research agreement. Together, the companies will evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm’s proprietary AbYlink conjugation technology for Alkyon’s modular antibody platform directed against undisclosed tumor-associated antigens. The goal is to create more effective, better-t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters